Checkpoint inhibition with PD-L1 blockade after chemoradiotherapy (CRT) improved survival in unresectable stage III NSCLC, as shown in the PACIFIC trial, with median PFS (mPFS) of 16.9 months versus 5.6 months and median overall survival (mOS) of 47.5 months versus 29.1 months. This evidence concerns the gene CD274 and non-small cell lung carcinoma.